| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash and cash equivalents provided by financing activities | 101,512 | 101,565 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 4,949 | -18,336 |
| Cash and cash equivalents at beginning of period | 37,107 | - |
| Cash and cash equivalents at end of period | 42,056 | - |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)